Santhera Pharmaceuticals : Todd Bazemore Steps Down from Role as Chief Operating Officer of Santhera’s US Subsidiary

Hammerstrasse 49

4410 Liestal / Switzerland Phone +41 61 906 89 50

Fax +41 61 906 89 51

www.santhera.com

Todd Bazemore, who has worked with Santhera since September of last year, will step down from his role as Chief Operating Officer for the US subsidiary, effective November 17, 2017. "We regret but respect Todd's decision," said Thomas Meier, PhD, CEO of Santhera who will assume Todd's responsibilities ad interim. "We would like to thank Todd for his engagement over the past year, and we wish him all the best for his future."

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative pharmaceutical products for the treatment of orphan mitochondrial and neuromuscular diseases. Santhera's lead product Raxone® (idebenone) is authorized in the European Union, Norway, Iceland, Liechtenstein and Israel for the treatment of Leber's hereditary optic neuropathy (LHON). For Duchenne muscular dystrophy (DMD), Santhera has filed a Marketing Authorization Application in the European Union and Switzerland for DMD patients with respiratory function decline who are not taking glucocorticoids. In collaboration with the

U.S. National Institute of Neurological Disorders and Stroke (NINDS) Santhera is developing Raxone® in a third indication, primary progressive multiple sclerosis (PPMS), and another product - omigapil

- for congenital muscular dystrophy (CMD), both also areas of high unmet medical need. For further information, please visit the Company's website www.santhera.com.

Raxone® is a trademark of Santhera Pharmaceuticals.

Sue Schneidhorst, Head Group Communications Europe: +41 61 906 89 26

US: +1 646 586 2113

sue.schneidhorst@santhera.com

Christoph Rentsch, Chief Financial Officer Hans Vitzthum, LifeSci Advisors Europe: +41 61 906 89 65 US: +1 212 915 2568

christoph.rentsch@santhera.com hans@lifesciadvisors.com

November 6, 2017 / Page 2 of 2

This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Santhera Pharmaceuticals Holding AG. This publication may contain certain forward- looking statements concerning the Company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the Company to be materially different from those expressed or implied by such statements. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. The Company disclaims any obligation to update these forward-looking statements.

# # #